Iama Therapeutics Announced To Sign A Multi-phase Agreement With Evotec
Portfolio Pulse from Benzinga Newsdesk
Iama Therapeutics has signed a multi-phase agreement with Evotec. Under the agreement, Evotec will provide preclinical and clinical services to support IAMA's Phase 1 clinical trial for its lead program IAMA-6, a therapeutic targeting NKCC1 for the treatment of autism and epilepsy.
October 02, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evotec's partnership with Iama Therapeutics could potentially increase its revenues and enhance its reputation in the biotech industry.
Evotec's partnership with Iama Therapeutics to support the Phase 1 clinical trial for IAMA-6 could potentially increase its revenues from the provision of preclinical and clinical services. Additionally, this partnership could enhance Evotec's reputation in the biotech industry, potentially attracting more partnerships in the future.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80